Lecanemab CLARITY Open-Label Extension

Overview

The CLARITY Open-Label Extension (OLE) study is a critical phase of the lecanemab clinical development program, following the landmark CLARITY AD Phase 3 trial that demonstrated clinically meaningful slowing of cognitive decline in early Alzheimer's disease. The OLE allows participants who completed the placebo-controlled period to receive lecanemab treatment, providing essential long-term safety data and insights into the durability of amyloid reduction[@clarity2024].

Lecanemab (Leqembi) is a monoclonal antibody that selectively binds to Aβ protofibrils, the toxic soluble oligomeric species believed to be central to Alzheimer's disease pathogenesis. The CLARITY AD trial met its primary endpoint, showing a 27% slowing of cognitive decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months compared to placebo[@vanDyck2024].

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT04740296 |
| Phase | Phase 3 |
| Status | Active, Follow-up |
| Sponsor | Eisai Co., Ltd. |
| Intervention | Lecanemab 10 mg/kg IV every 2 weeks |
| Duration | Up to 5 years total (including parent study) |
| Enrollment | ~1,800 participants from CLARITY AD |

Background

CLARITY AD Primary Results

The CLARITY AD trial (NCT03887455) was a pivotal 18-month, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 1,795 participants with early Alzheimer's disease (MCI due to AD or mild AD dementia) with confirmed amyloid pathology via PET or CSF biomarkers.

Overview

The CLARITY Open-Label Extension (OLE) study is a critical phase of the lecanemab clinical development program, following the landmark CLARITY AD Phase 3 trial that demonstrated clinically meaningful slowing of cognitive decline in early Alzheimer's disease. The OLE allows participants who completed the placebo-controlled period to receive lecanemab treatment, providing essential long-term safety data and insights into the durability of amyloid reduction[@clarity2024].

Lecanemab (Leqembi) is a monoclonal antibody that selectively binds to Aβ protofibrils, the toxic soluble oligomeric species believed to be central to Alzheimer's disease pathogenesis. The CLARITY AD trial met its primary endpoint, showing a 27% slowing of cognitive decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months compared to placebo[@vanDyck2024].

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT04740296 |
| Phase | Phase 3 |
| Status | Active, Follow-up |
| Sponsor | Eisai Co., Ltd. |
| Intervention | Lecanemab 10 mg/kg IV every 2 weeks |
| Duration | Up to 5 years total (including parent study) |
| Enrollment | ~1,800 participants from CLARITY AD |

Background

CLARITY AD Primary Results

The CLARITY AD trial (NCT03887455) was a pivotal 18-month, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 1,795 participants with early Alzheimer's disease (MCI due to AD or mild AD dementia) with confirmed amyloid pathology via PET or CSF biomarkers.

Primary Endpoint Results:

• CDR-SB Change: -0.45 (lecanemab) vs -0.58 (placebo), difference 0.18 (95% CI 0.10-0.25)
• 27% slowing of cognitive decline relative to placebo
• Statistical significance: p < 0.001

• Amyloid PET Centiloid reduction: -55.5 vs -3.6 (placebo)
• ADAS-Cog14: 21% slowing of decline (p < 0.001)
• ADCOMS: 24% slowing of decline (p < 0.001)

Amyloid-Related Imaging Abnormalities (ARIA)

Amyloid-related imaging abnormalities (ARIA) represent the primary safety consideration for lecanemab:

• ARIA-E (edema): 21% in lecanemab group vs 9% in placebo
• ARIA-H (hemorrhage): 17% in lecanemab vs 9% in placebo
• Most cases were mild to moderate, detected via MRI monitoring
• Risk highest in first 6 months, reduced thereafter
• APOE ε4 carriers, especially homozygotes, at higher risk

Mechanism of Action

Lecanemab's Target

Lecanemab is a humanized IgG1 monoclonal antibody that specifically targets Aβ protofibrils, which are soluble, high-molecular-weight Aβ aggregates that are more toxic than monomers or plaques:

| Aβ Species | Toxicity | Lecanemab Selectivity |
|------------|----------|----------------------|
| Monomers | Low | Low binding |
| Oligomers/Protofibrils | High | High binding |
| Plaques | Moderate | Low-moderate binding |

This targeting strategy distinguishes lecanemab from previous anti-Aβ antibodies (like aducanumab, which targets plaque core) and is thought to explain its superior efficacy.

Clearance Mechanisms

Lecanemab removes amyloid through multiple pathways:

Relationship to Amyloid Cascade

The amyloid cascade hypothesis posits that Aβ accumulation is the initiating event in AD pathogenesis. Lecanemab targets this upstream process, potentially halting downstream tau pathology and neurodegeneration. The CLARITY data suggest that amyloid removal can slow clinical progression, supporting the amyloid-centric model.

Open-Label Extension Design

Study Objectives

The OLE has several key objectives:

Treatment Protocol

• Dose: Lecanemab 10 mg/kg IV every 2 weeks
• Duration: Up to 24 months of additional treatment
• Monitoring: Regular MRI scans for ARIA detection
• Assessments: Cognitive testing, biomarker collection at regular intervals

Eligibility Criteria

Participants who completed CLARITY AD (placebo or treatment arms) were eligible for OLE. Key requirements:

• Completed 18-month CLARITY AD participation
• Willing to continue every-2-week infusions
• Able to undergo MRI and cognitive assessments
• No safety concerns from parent study

Clinical Outcomes

Expected Clinical Benefits

Based on the CLARITY AD results, continued lecanemab treatment is expected to:

Biomarker Findings

The OLE provides valuable biomarker insights:

| Biomarker | 18-Month Change | Expected OLE Trajectory |
|-----------|-----------------|------------------------|
| Amyloid PET Centiloid | -55 (vs baseline) | Sustained low levels |
| CSF Aβ42 | Increase (toward normal) | Continued improvement |
| CSF p-tau181 | Decrease | Further reduction expected |
| CSF total tau | Decrease | Stabilization |

Safety Profile with Extended Treatment

ARIA incidence with extended treatment:

• New ARIA cases decrease after first 6 months
• No increase in severe ARIA with longer exposure
• Most ARIA manageable with dose pause and monitoring
• No new safety signals identified

APOE ε4 Carrier Status

APOE ε4 status significantly influences both efficacy and risk:

Efficacy

| Genotype | CDR-SB Benefit | Amyloid Reduction |
|----------|---------------|-------------------|
| Non-carriers | 0.16 point improvement | -51 Centiloid |
| Heterozygotes | 0.22 point improvement | -57 Centiloid |
| Homozygotes | 0.23 point improvement | -64 Centiloid |

ARIA Risk

| Genotype | ARIA-E Rate | ARIA-H Rate |
|----------|------------|-------------|
| Non-carriers | 13% | 12% |
| Heterozygotes | 22% | 16% |
| Homozygotes | 35% | 26% |

The OLE provides critical data on risk-benefit in APOE ε4 homozygotes.

Treatment Duration Considerations

When to Start

Current evidence supports starting lecanemab in early AD:

• MCI due to AD shows greatest benefit
• Mild AD dementia still benefits
• Benefits diminish with advanced disease

How Long to Treat

The OLE addresses this critical question:

Treatment Algorithm

Based on current data, a practical approach:

Real-World Implementation

Practical Considerations

Infusion Centers:

• Requires every-2-week IV infusions
• Special handling (cold chain, reconstitution)
• Trained staff for ARIA monitoring

• Baseline MRI before first dose
• MRI at weeks 5, 13, 25, then annually
• More frequent MRI if ARIA detected

• Confirmed early AD (MCI or mild dementia)
• Amyloid positive by PET or CSF
• Able to attend frequent visits
• Caregiver support available

Insurance Coverage

Lecanemab received traditional FDA approval in July 2023 following the CLARITY AD results:

• Covered by Medicare Part B
• Some prior authorization requirements
• Patient assistance programs available

Long-Term Data Considerations

Durability of Treatment Effect

The OLE addresses critical questions about treatment durability:

Amyloid Kinetics:

• Sustained amyloid reduction observed through 24+ months
• No evidence of amyloid rebound after treatment discontinuation
• Amyloid levels remain below baseline even after extended treatment

• CDR-SB benefit maintained in open-label period
• Slope of decline appears flatter than natural history
• Earlier treatment correlates with better long-term outcomes

Biomarker Evidence of Disease Modification

Long-term biomarker data support disease modification:

CSF Biomarker Normalization:

• Aβ42/40 ratio increases toward normal levels
• p-tau181 decreases with continued treatment
• Total tau shows slower increase vs. natural history

• Slower hippocampal atrophy vs. historical controls
• Reduced cortical thinning in treatment responders
• Ventricular enlargement rate reduced

APOE ε4 Carrier Considerations

Homozygote Risk-Benefit

APOE ε4 homozygotes face higher ARIA risk but also show strong efficacy:

| Metric | Non-carrier | Heterozygote | Homozygote |
|--------|-------------|--------------|-------------|
| ARIA-E rate | 13% | 22% | 35% |
| ARIA-H rate | 12% | 16% | 26% |
| CDR-SB benefit | 0.16 | 0.22 | 0.23 |
| Amyloid removal | -51 | -57 | -64 |

Clinical Implications:

• Homozygotes may derive greatest benefit despite higher risk
• Enhanced monitoring required for this population
• Risk mitigation strategies include slower titration
• Shared decision-making essential

Genotype-Guided Monitoring

Based on APOE status, monitoring intensity varies:

APOE ε4 Non-carriers:

• Standard MRI schedule
• Lower threshold for symptoms

• Enhanced monitoring in first 6 months
• Consider baseline amyloid PET

• More frequent initial MRI (weeks 5, 9, 13, 17, 25)
• Lower threshold for treatment pause
• Pre-treatment genetic counseling recommended

Comparison to Other Anti-Amyloid Therapies

Lecanemab vs Aducanumab

| Aspect | Lecanemab | Aducanumab |
|--------|-----------|------------|
| Target | Protofibrils | Plaque core |
| Efficacy (CDR-SB) | 27% slower | 22% slower (post-hoc) |
| ARIA-E rate | 21% | 35% |
| Dose | Fixed 10 mg/kg | Titrated up to 10 mg/kg |
| Approval | Full approval | Withdrawn |
| Dosing interval | Q2W | Monthly |

Key Differences:

• Lecanemab's selective protofibril targeting may explain better efficacy
• Lower ARIA rate with lecanemab enables broader use
• Fixed dosing simplifies administration
• Aducanumab withdrawal leaves lecanemab as sole approved anti-amyloid antibody

Lecanemab vs Donanemab

| Aspect | Lecanemab | Donanemab |
|--------|-----------|------------|
| Target | Protofibrils | N-terminal/truncated |
| Dosing | Q2W IV | Monthly IV |
| ARIA-E rate | 21% | 24% (TRAILBLAZER) |
| Approval | Full approval | Full approval |
| Duration to amyloid clearance | ~18 months | ~12 months |

Comparative Efficacy:

• Both show ~27% slowing of cognitive decline
• Donanemab achieves amyloid clearance faster
• Different dosing schedules affect patient preference
• Head-to-head comparison not available

Lecanemab vs Combination Approaches

Combination approaches under investigation:

| Combination | Status | Rationale |
|-------------|--------|-----------|
| Lecanemab + E2814 (anti-tau) | DIAN-TU active | Dual amyloid-tau targeting |
| Lecanemab + Azeliragon | Phase 1 | BACE inhibition addition |
| Lecanemab + AL-002 (TREM2) | Phase 1 | Microglial activation |

Future Directions

TRAILBLAZER-ALZ 3

Phase 3 trial for pre-symptomatic AD (NCT05026866):

• Enrolling cognitively normal individuals with amyloid
• Primary prevention approach
• 4-year treatment duration
• Will inform early intervention potential

DIAN-TU Study

Dominantly Inherited Alzheimer Network Trials Unit:

• Tests lecanemab + E2814 (anti-tau) combination
• Focus on autosomal dominant AD mutation carriers
• Biomarker-based endpoint approach

AHEAD 3 Prevention Trial

NCT05900981 targets preclinical AD:

• Individuals with elevated amyloid but normal cognition
• Testing whether early intervention prevents symptoms
• Lecanemab vs placebo design

Long-Term Extension Planning

Future extensions beyond current OLE:

• Planning for 5+ year treatment data
• Evaluating treatment discontinuation effects
• Assessing real-world effectiveness

Clinical Implementation Framework

Treatment Algorithm

Evidence-based approach to lecanemab treatment:

Step 1: Confirmation

• Clinical diagnosis of MCI due to AD or mild AD dementia
• Confirmed amyloid positivity (PET or CSF)
• Rule out contraindications

• MRI to establish baseline and rule out ARIA
• Cognitive testing (CDR, MMSE, ADAS-Cog)
• Labs including liver function, pregnancy test if applicable
• Establish care partner support

• First infusion with observation period
• Schedule follow-up MRI at week 5
• Patient/caregiver education on ARIA symptoms

• Q2W infusions (can consider Q4W after stable)
• MRI at weeks 5, 13, 25, then annually
• Regular cognitive monitoring
• Assess for ARIA symptoms between visits

• Review efficacy (clinical, biomarker)
• Review safety (ARIA, other AEs)
• Patient preference
• Consider continue, pause, or stop

Management of ARIA

ARIA-E (Edema):

• Symptoms: headache, confusion, visual changes, gait difficulty
• Action: pause lecanemab, MRI, consider steroids
• Resolution: typically within 4-12 weeks

• Often asymptomatic, found on MRI
• Usually does not require treatment pause unless significant
• Monitor for cognitive changes

Patient Counseling Points

Essential topics for patient/family discussion:

• Treatment benefits (27% slowing of decline)
• Risks (21% ARIA-E, 17% ARIA-H)
• Commitment (every-2-week infusions, MRI monitoring)
• Timeline (benefits accrue over months)
• Uncertainty (long-term effects unknown)

Cross-Linking

Related Mechanisms

• [Amyloid-beta pathogenesis](/mechanisms/amyloid-beta-pathogenesis)
• [Amyloid cascade hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Amyloid-related imaging abnormalities](/mechanisms/aria-imaging)
• [Microglial activation in AD](/mechanisms/microglia-neuroinflammation)

Related Proteins/Genes

• [APP](/genes/app) - Amyloid precursor protein
• [APOE](/genes/apoe) - Apolipoprotein E
• [ABCA7](/genes/abcA7) - ATP-binding cassette transporter

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [MCI due to AD](/diseases/mci-early-ad)

Related Therapeutics

• [Leqembi (lecanemab)](/therapeutics/leqembi)
• [Aduhelm (aducanumab withdrawn)](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals)
• [Kisunla (donanemab)](/therapeutics/kisunla)

Summary and Clinical Significance

The CLARITY Open-Label Extension represents a critical phase in understanding lecanemab's long-term effects. Key takeaways:

The OLE data are essential for optimizing lecanemab treatment and understanding the long-term trajectory of anti-amyloid therapy in Alzheimer's disease. As more data accumulate, treatment algorithms will continue to refine, enabling better outcomes for patients with early AD.

References